NDARC has been invited to undertake research in partnership with NSW Aboriginal drug and alcohol Residential Rehabilitation Services. This research is unique in being embedded into the routine delivery of their services.
Alcohol and other drug (AOD) treatment is key for improving health and reducing the social impact of AOD use. However, the treatment itself is not the only variable that impacts on whether health outcomes are improved.
The Australian National Advisory Council on Alcohol and Drugs (ANACAD) has funded NDARC to conduct a feasibility study for an early warning system (EWS) project, involving a data collection model that allows rapid triangulation of existing data to provide an early warning and current assessment o
The Climate and Preventure (CAP) study was initiated in 2011 by Nicola Newton, Maree Teesson, Tim Slade and Patricia Conrod as a school-based prevention initiative targeting alcohol and drug use.
This project is an international collaboration to assess the nature and extent of health outcomes from drug cryptomarkets, globally and specifically for Australians.
In partnership with Gilimbaa, an Indigenous Creative Agency, this project involves development of culturally appropriate school-based resources to prevent drug-related harms among young Aboriginal and Torres Strait Islander people.
This project seeks to develop knowledge about effective models of partnership between rural Aboriginal communities and researchers across a range of community-led programs delivered from 2012-2016, which aimed to reduce drug and alcohol-related harm.
Substance use among pregnant women is a significant public health issue. A range of adverse effects have been noted including increased risk of miscarriage and still birth, reduction in fetal growth, birth defects, developmental delay, growth retardation and neurological abnormalities.
It has been argued that the increased influence of conservative advocacy groups and the impact of the political social conservatism of ‘The Howard Years’ has led to a conservative shift in Australian drug policy, away from harm minimisation and towards a zero tolerance model (Mendes, 2001,